Related Experiment Video
Updated: Mar 26, 2026

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study
Sergio Crovella1, Anna Monica Bianco1, Joseph Vuch1
1a Institute for Maternal and Child Health, IRCCS Burlo Garofolo , Trieste , Italy.
Abstract:
Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. The development of MPM is frequently linked to inhalation of asbestos fibers. A genetic component of susceptibility to this disease is suggested by the observation that some individuals develop MPM following lower doses of asbestos exposure, whereas others exposed to higher quantities do not seem to be affected. This hypothesis is supported also by frequent reports of MPM familial clustering. Despite the widely recognized role of iron (Fe) in cellular asbestos-induced pulmonary toxicity, the role of the related gene polymorphisms in the etiology of MPM has apparently not been evaluated. Eighty-six single-nucleotide polymorphisms (SNPs) of 10 Fe-metabolism genes were examined by exploiting formalin-fixed paraffin-embedded postmortem samples from 77 patients who died due to MPM (designated AEM) and compared with 48 who were exposed to asbestos but from died in old age of cause other than asbestos (designated AENM). All subjects showed objective signs of asbestos exposure. Three SNPs, localized in the ferritin heavy polypeptide, transferrin, and hephaestin genes, whose frequencies were distributed differently in AEM and AENM populations, were identified. For ferritin and transferrin the C/C and the G/G genotypes, respectively, representing intronic polymorphisms, were significantly associated with protection against MPM and need to be considered as possible genetic markers of protection. Similarly, the C/C hephaestin SNP, a missense variation of this multicopper ferroxidase encoding gene, may be related, also functionally, with protection against MPM. In conclusion, it is proposed that three Fe metabolism-associated genes, significantly associated with protection against development of MPM, may serve as protective markers for this aggressive tumor.
Insights
Genetic variations in iron metabolism genes, specifically ferritin, transferrin, and hephaestin, may offer protection against malignant pleural mesothelioma (MPM) development following asbestos exposure.
Area of Science:
- Environmental Health
- Genetics
- Oncology
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive cancer often linked to asbestos exposure.
- Individual susceptibility to MPM varies, suggesting a genetic component.
- The role of iron (Fe) metabolism gene polymorphisms in MPM etiology was previously unevaluated.
Purpose of the Study:
- To investigate the association between single-nucleotide polymorphisms (SNPs) in iron metabolism genes and susceptibility to malignant pleural mesothelioma.
- To identify potential genetic markers for protection against asbestos-induced MPM.
Main Methods:
- Eighty-six SNPs from 10 Fe-metabolism genes were analyzed.
- Formalin-fixed paraffin-embedded postmortem samples from 77 MPM patients (AEM) and 48 asbestos-exposed non-MPM individuals (AENM) were used.
- Genotype frequencies were compared between the AEM and AENM groups.
Main Results:
- Three SNPs in the ferritin heavy polypeptide, transferrin, and hephaestin genes showed different frequencies between AEM and AENM groups.
- The C/C genotype in ferritin and the G/G genotype in transferrin were associated with protection against MPM.
- The C/C hephaestin SNP (a missense variation) may also be functionally related to MPM protection.
Conclusions:
- Specific iron metabolism gene polymorphisms are associated with protection against malignant pleural mesothelioma.
- Ferritin, transferrin, and hephaestin gene variations may serve as protective genetic markers for MPM.
- Further research into these Fe metabolism-associated genes could inform strategies for mitigating MPM risk.

